Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SOPHiA GENETICS SA (Nasdaq: SOPH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. SOPHiA GENETICS files reports such as Form 20-F and Form 6-K with the U.S. Securities and Exchange Commission, offering detailed information on its financial condition, operations, and material announcements related to its AI-powered healthcare technology business.
Recent Form 6-K filings have included unaudited interim condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and press releases covering quarterly results and business updates. These documents give investors insight into revenue trends, non-IFRS measures such as adjusted gross profit and adjusted EBITDA, geographic revenue breakdowns, and segment information that includes the SOPHiA DDM™ Platform and workflow equipment and services.
Through this page, users can review how SOPHiA GENETICS reports on topics such as platform usage, analysis volumes, regional performance, and capital structure. Filings may also reference warrant liabilities, credit agreements, and other financial instruments, along with discussions of constant currency revenue and other metrics used by management to evaluate performance.
Stock Titan enhances these filings with AI-powered summaries that explain key points in accessible language, helping readers understand complex sections of financial statements and management commentary. Users can quickly identify important themes in SOPHiA GENETICS’ 20-F annual reports, 6-K current reports, and other submissions, and then drill into the original documents for more detail.
In addition, this page offers convenient access to information relevant to governance and capital markets activity, such as exhibits attached to 6-Ks and references to registration statements. While SOPHiA GENETICS is not a U.S. domestic issuer and does not file Forms 10-K or 10-Q, its 20-F and 6-K filings serve a similar role for investors analyzing SOPH stock and the company’s AI-driven precision medicine platform.
SOPH filing (Form 144) reports proposed sales of Common Stock, showing multiple 10b5-1 sales by Zhenyu Xu and scheduled dispositions of restricted and founder shares. Examples include 4,414 shares sold on 04/13/2026 for $21,026.97 and a 608-share RSU entry dated 04/18/2026.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice related to SOPH common stock, reporting 760 shares of restricted stock units to be sold on 04/18/2026. The filing also lists multiple 10b5-1 sales by Ross J. Muken during Feb–Apr 2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting a proposed sale of 684 Restricted Stock Units (Common) dated 04/18/2026. The filing also lists recent 10b5-1 sales by Daan Guido Maria van Well, including 2,400 shares on 04/10/2026 for $11,201.28 and 2,861 shares on 04/08/2026 for $13,862.12.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported an open-market sale of 600 ordinary shares on April 14, 2026 at a weighted average price of $4.9663 per share. The sale was executed under a pre-arranged Rule 10b5-1(c) trading plan, and Xu continued to hold 631,496 ordinary shares directly after the transaction.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported routine share sales tied to tax obligations. On April 14 and 15, 2026, he sold a total of 60,602 ordinary shares in open-market transactions at weighted average prices of $4.9580 and $5.0021 per share. The filing states these sales were executed to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026, under a pre-established Rule 10b5-1(c) trading plan, meaning they were not discretionary trades. After these transactions, he continues to hold 3,646,967 ordinary shares directly.
Chief Medical Officer Philippe Menu of SOPHiA GENETICS SA sold 1,600 ordinary shares in an open-market transaction on April 14, 2026. The shares were sold at a weighted average price of $4.9581 per share under a pre-established Rule 10b5-1(c) trading plan.
Following this sale, Menu directly holds 266,996 ordinary shares. The transaction was executed through multiple trades at prices ranging from $4.78 to $5.16 per share.
SOPHiA GENETICS SA President Ross Muken completed an open-market sale of 2,800 Ordinary Shares at a weighted average price of $4.9597 per share. After this transaction, he directly holds 682,432 shares. The sale was made to cover tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026 and was executed under a pre-established Rule 10b5-1(c) trading plan, meaning it did not represent a discretionary trade.
SOPHiA GENETICS SA Chief Legal Officer Daan Van Well reported selling 2,400 Ordinary Shares of SOPH on April 10, 2026 at a weighted average price of $4.6672 per share. The footnotes state these shares were sold in the open market solely to satisfy tax withholding obligations from restricted stock units vesting on April 2 and 3, 2026.
The sales were executed under a pre-established Rule 10b5-1(c) trading plan and are described as non-discretionary. After the transaction, Van Well directly holds 346,420 Ordinary Shares, indicating he retained a substantial equity position in the company.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported open‑market sales of 8,120 Ordinary Shares of SOPH. The shares were sold on April 10 and April 13, 2026 at weighted average prices around $4.68–$4.76 per share.
According to the disclosure, these sales were made to satisfy tax withholding obligations tied to restricted stock units that vested on April 2 and 3, 2026, and were carried out under a pre‑established Rule 10b5‑1(c) trading plan. Following the transactions, Xu continues to hold 632,096 Ordinary Shares directly.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported open-market sales of 16,631 ordinary shares of SOPH. The shares were sold on April 10 and 13, 2026 at weighted average prices around $4.72–$4.76 per share.
Footnotes state these transactions were effected under a pre-established Rule 10b5-1(c) trading plan to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026, and are not discretionary trades. After these sales, Camblong continues to hold 3,707,569 ordinary shares directly.